Impact of rhinovirus nasopharyngeal viral load and viremia on severity of respiratory infections in children

S. Esposito · C. Daleno · A. Scala · L. Castellazzi · L. Terranova · S. Sferrazza Papa · M. R. Longo · C. Pelucchi · N. Principi

Abstract There are few and partially discordant data regarding nasopharyngeal rhinovirus (RV) load and viremia, and none of the published studies evaluated the two variables together. The aim of this study was to provide new information concerning the clinical relevance of determining nasopharyngeal viral load and viremia when characterising RV infection. Nasopharyngeal swabs were obtained from 251 children upon their admission to hospital because of fever and signs and symptoms of acute respiratory infection in order to identify the virus and determine its nasopharyngeal load, and a venous blood sample was taken in order to evaluate viremia. Fifty children (19.9 %) had RV-positive nasopharyngeal swabs, six (12 %) of whom also had RV viremia: RV-C in four cases (66.6 %), and RV-A and RV-B in one case each. The RV nasopharyngeal load was significantly higher in the children with RV viremia ($p<0.001$), who also had a higher respiratory rate ($p=0.02$), white blood cell counts ($p=0.008$) and C-reactive protein levels ($p=0.006$), lower blood O$_2$ saturation levels ($P=0.005$), and more often required O$_2$ therapy ($p=0.009$). The presence of RV viremia is associated with a significantly higher nasopharyngeal viral load and more severe disease, which suggests that a high nasopharyngeal viral load is a prerequisite for viremia, and that viremia is associated with considerable clinical involvement.

Introduction

Rhinoviruses (RVs), which are frequently found in the nasopharynx of patients with respiratory disease [1], were identified some years ago and, although they have been widely studied, many aspects of their role in causing respiratory infections remain unclear. They were initially considered to have little medical significance because they were only isolated in subjects with upper respiratory tract infections (RTIs), mainly common colds [1]. However, the more recent availability of modern molecular methods of viral screening [2] has led to them being identified in the nasopharyngeal secretions of subjects with bronchitis, bronchiolitis and pneumonia, and it has been demonstrated that they are frequently associated with asthma exacerbations [3–8].

The real etiological role of RVs is difficult to ascertain. As they are shed in respiratory secretions for several days after the clinical resolution of an acute episode of RTI, their presence in the nasopharynx of a subject with acute RTI may only be due to prolonged shedding after a previous infection and is not proof that they caused the new disease [9–12]. Knowing the importance of RVs is critical for deciding the need for new preventive and therapeutic strategies, particularly in the case of lower RTIs. It has recently been suggested that simultaneously determining nasopharyngeal RV load and identifying RV viremic cases could differentiate the respiratory infections in which RV is the real causative agent [12]. However, the published data are few and partially discordant, and no study has yet evaluated the two variables together [13–20]. Moreover, there are no published data concerning the possible relationships between RV nasopharyngeal viral load, viremia and the severity of RV-associated disease.

The aim of this study was to provide new information concerning the clinical relevance of determining nasopharyngeal viral load and viremia when characterising RV infection.
Methods

Patient enrolment

The study was approved by the Institutional Review Board of the University of Milan, Milan, Italy, and was prospectively carried out at Pediatric Clinic 1 of the Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy, between 1 November 2011 and 31 March 2012. The written informed consent of a parent or legal guardian was required, and the older children were asked to give their assent.

All of the children aged between 1 month and 14 years admitted to Pediatric Clinic 1 because of fever (i.e. an axillary temperature >38 °C) and signs and symptoms of acute RTI with an onset of less than 24 h before (i.e. rhinorrhea, cough, tachypnea, dyspnea or respiratory distress, and breathing with grunting or wheezing sounds with rales) were considered eligible for the study. The exclusion criteria were symptom onset more than 24 h before and chronic conditions increasing the risk of respiratory infections, including premature birth; chronic disorders of the pulmonary or cardiovascular systems; chronic metabolic diseases; neoplasia; kidney or liver dysfunction; hemoglobinopathies; immunosuppression; diseases requiring long-term aspirin therapy; and genetic or neurological disorders. The diagnoses of RTIs (upper RTI: common cold and pharyngitis; lower RTI: bronchitis, bronchiolitis, infectious wheezing and pneumonia) were based on well-defined clinical and laboratory criteria [21]. All of the children with lower RTI underwent chest radiography, and the radiograph was evaluated by an independent expert radiologist who confirmed pneumonia using the World Health Organisation (WHO) criteria for the standardised interpretation of pediatric chest radiographs for a diagnosis of pneumonia [22].

On the day of enrolment, a nasopharyngeal swab of respiratory secretions was taken using a pernasal flocked swab, and stored in a tube of UTM-RT (Kit Cat. No. 360c, Copan Italia, Brescia, Italy), and a blood sample was drawn using standard procedures. Nasopharyngeal swab was used because it is the simplest sampling method for the identification of respiratory viruses without any reduction in diagnostic performance in comparison to nasopharyngeal aspiration and nasal washes. Moreover, it has the advantages of improved standardization in different age groups and between operators, and better acceptability in a wider range of settings [23]. One swab per patient was collected. Plasma was obtained by centrifuging an aliquot of 10 mL of whole blood at 2,500 rpm for 15 min, some of which was used to determine RV viremia, and the rest for the other laboratory variables, including a white blood cell (WBC) count, the measurement of C-reactive protein (CRP) levels, and the preparation of blood cultures.

The viral tests were performed for study purposes and were always available after discharge. Upon enrolment, detailed information was recorded concerning the patients’ demographics and history, and the clinical characteristics of the disease. The children with pneumonia received antibiotic therapy in accordance with the guidelines of the Expert Committee of the European Society for Paediatric Infectious Diseases [24]. All of the children with mild disease returned home and were followed up by means of a bi-weekly telephone call until clinical cure. The children with more severe disease were hospitalised and monitored daily until discharge.

Respiratory viral analyses of nasopharyngeal swabs

Viral RNA or DNA was extracted from the nasopharyngeal swabs by means of a Nuclisens EasyMAG automated extraction system (Biomerieux, Craponne, France), and the extracts were tested using the RVP Fast assay (Luminex Molecular Diagnostics Inc., Toronto, Canada) in accordance with the manufacturer’s instructions. The RVP Fast assay simultaneously detects influenza A virus (subtyped H1 or H3), influenza B virus, RSV-A and -B, parainfluenza-1, -2, -3, and -4, adenovirus, human metapneumovirus, coronaviruses 229E, NL63, OC43, and HKU1, enterovirus/RV, and human bocavirus [25, 26].

The enterovirus/RV-positive nasopharyngeal samples were retested in order to identify the rhinovirus and determine viral load. The real-time RT-PCR assay was performed using the iAg-Path-ID one-step RT-PCR Kit (Applied Biosystems, Foster City, CA), the primers and probe sequences reported by Lu et al. [27], and previously described methods [6].

The hypervariable part of the 5′ NCR, the entire VP4 gene, and the 5′ terminus of the VP2 gene were amplified using an RT-PCR assay as previously described [28], with minor modifications. The eluted RNA was transcribed into cDNA using Moloney Murine Reverse Transcriptase (MMLV-RT, Invitrogen, Monza, Italy) and random hexamers for 1 h at 37 °C, and the MMLV-RT was subsequently denatured at 70 °C. The PCR was carried out in a final volume of 50 μL containing the virus-specific oligonucleotide primers (0.2 mM each), 2 U AmpliTaq Gold 360 DNA Polymerase (Applied Biosystems), 1x reaction buffer, 0.2 mM each of dNTP, 2 mM MgCl₂ and 2 mL of cDNA template. The 40 PCR cycles consisted of a denaturation step (45 s at 95 °C), an annealing step (45 s at 61 °C), and a DNA extension step (1 min at 72 °C). The presence of 549 bp PCR products was visualised after electrophoresis on an ethidium bromide-stained 2 % agarose gel.

The PCR products were purified using the Wizard SV Gel and PCR Clean-Up System (Promega, Milan, Italy), and the purified products were sequenced in both directions using the same forward and reverse primers as those used in the PCR. The nucleotide sequences were obtained by means of automated DNA sequencing using an ABI PRISM 3730 genetic analyser (Applied Biosystems). In order to identify the RV species (A, B and C), the newly determined sequences were checked and aligned using the BioEdit program, and the resultant consensus sequences were compared with sequences...
from GenBank using the nucleotide-nucleotide BLAST algorithm (http://www.ncbi.nlm.nih.gov). The analysed fragment was 400 nt in the VP4/VP2 region.

A plasmid containing the corresponding target viral sequence (kindly provided by Dr Baldanti, Molecular Virology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy) was then used to quantify the positive samples. Ten-fold plasmid serial dilutions ranging from 5 to 5×10⁷ input copies were prepared to generate calibration curves and then run in parallel with the tested samples. The cycle threshold (Ct) values of each dilution were measured in duplicate, and plotted against the logarithm of their initial quantities. The copy numbers present in each clinical sample were derived from the regression line. The quantitative results were expressed as log₁₀ RNA copy numbers/mL nasopharyngeal swab following data multiplication by the appropriate dilution factor. In order to evaluate reproducibility, intra-assay and interassay standard deviations (SDs) and coefficients of variation (CVs) were calculated for each standard concentration within and between the individual PCR runs. Each run included template and non-template controls.

Determination of RV viremia

RV viremia was only analysed in the plasma samples of patients with RV-positive nasopharyngeal swabs. RNA was extracted using a Nuclisens EasyMAG automated extraction system in accordance with the manufacturer’s instructions, and the extracts were tested by means of quantitative real-time RT-PCR using the same primers and methods as those used to measure the viral load of the nasopharyngeal specimens. The nasopharyngeal and plasma samples were handled separately in order to prevent cross-contamination.

Statistical analysis

The continuous variables are given as mean values ± standard deviation (SD), and were analysed using a non-parametric Wilcoxon rank-sum test or the Kruskal-Wallis test as appropriate. The categorical variables are given as numbers and percentages, and were analysed by means of contingency tables and the chi-squared or Fisher’s exact test as appropriate. All of the tests were two-sided and a p value of <0.05 was considered statistically significant. The data were analysed using SAS version 9.1 statistical software (SAS Institute, Cary, NC, USA).

Results

Fifty (19.9 %) of the 251 children enrolled (157 males, 62.5 %; mean age±SD, 2.9±3.7 years) had RV-positive nasopharyngeal swabs. RV was the only virus identified in 31 cases (62.0 %), whereas it was detected with two other viruses in 18 cases (36.0 %) and with three other viruses in one (2.0 %). The RV was RV-A in 18 cases (36.0 %), RV-B in five (10.0 %), RV-C in 22 (44.0 %), and untypeable in five (10.0 %). Viremia was identified in six cases (12 %): RV-C in four (66.6 %), and RV-A and RV-B in one case each.

Table 1 shows that nasopharyngeal RV load was independent of all of the studied variables, including the demographic data, disease diagnosis, respiratory rate, O₂ saturation, the need for O₂ therapy, hospitalisation, admission to an intensive care unit, and the laboratory findings. The blood cultures of all of the patients were negative. The only significant relationship seemed to be the presence of RV viremia: the plasma-positive children had a significantly higher nasopharyngeal RV load (7.90±1.07 log₁₀ cp/mL vs 5.15±1.53 log₁₀ cp/mL; p<0.001).

Table 2 summarises the characteristics of the patients with RV-positive nasopharyngeal swabs on the basis of their plasma RV results. In comparison with the patients without RV viremia, the children with RV viremia were significantly more frequently female (p=0.03) and, at the time of enrolment, had a significantly higher respiratory frequency (p=0.02), significantly lower O₂ blood saturation levels (p=0.005), required O₂ therapy significantly more often (p=0.009), and had significantly higher WBC counts (p=0.008) and C reactive protein levels (p=0.006). Moreover, nasopharyngeal viral load was significantly higher in the children with RV viremia (p=0.02).

Table 3 shows nasopharyngeal RV load in the children with and without viremia by type of RV. RV was the only infectious agent identified in the nasopharynx of RV viremic patients, who had higher mean nasopharyngeal loads of all of the RV types. However, given the limited number of viremic patients with RV-A or RV-B infection, the only significant difference in nasopharyngeal viral load was observed in the case of the children infected by RV-C (p=0.03). RV detected in blood was always of the same type of RV detected in nasopharyngeal secretions.

Discussion

Our findings confirm that RVs are frequently found in the nasopharynx of children with respiratory diseases (regardless of the site of infection), sometimes together with one or more other respiratory viruses [6, 8]. In terms of clinical relevance, we did not find any positive correlation between nasopharyngeal RV load and the type of respiratory infection diagnosed, but the children who were positive for RV viremia simultaneously had a significantly higher viral load and more severe disease, thus suggesting that the former is a prerequisite for viremia and is more frequently associated with greater clinical involvement. The lack of a correlation between nasopharyngeal
| Characteristics                        | n   | Mean nasopharyngeal RV load (log_{10} cp/mL) | Standard deviation | P value<br> |
|---------------------------------------|-----|-------------------------------------------|-------------------|------------|
| **Age**                               |     |                                           |                   |            |
| <1 year                               | 17  | 5.80                                      | 1.78              |            |
| ≥1 year                               | 33  | 5.32                                      | 1.70              | 0.23       |
| **Gender**                            |     |                                           |                   |            |
| Male                                  | 30  | 5.33                                      | 1.67              |            |
| Female                                | 20  | 5.70                                      | 1.82              | 0.61       |
| **Diagnosis**                         |     |                                           |                   |            |
| Upper respiratory tract infection     | 25  | 5.37                                      | 1.81              |            |
| Bronchiolitis/bronchitis              | 9   | 5.63                                      | 1.21              |            |
| Pneumonia/bronchopneumonia            | 16  | 5.30                                      | 1.89              | 0.76       |
| **Respiratory rate upon enrolment**   |     |                                           |                   |            |
| Normal                                | 16  | 5.01                                      | 1.76              |            |
| Higher than normal                    | 7   | 6.02                                      | 2.34              | 0.37       |
| **O₂ saturation upon enrolment**      |     |                                           |                   |            |
| <93 %                                 | 8   | 6.49                                      | 2.36              |            |
| ≥93 %                                 | 40  | 5.30                                      | 1.56              | 0.13       |
| **O₂ therapy**                        |     |                                           |                   |            |
| No                                    | 34  | 5.30                                      | 1.63              |            |
| Yes                                   | 16  | 5.85                                      | 1.92              | 0.24       |
| **No. of days of O₂ therapy**         |     |                                           |                   |            |
| <3                                    | 3   | 6.71                                      | 1.45              |            |
| ≥3                                    | 13  | 5.66                                      | 2.01              | 0.35       |
| **Hospitalisation**                   |     |                                           |                   |            |
| No                                    | 20  | 5.60                                      | 1.77              |            |
| Yes                                   | 30  | 5.40                                      | 1.72              | 0.62       |
| **No. of days of hospitalisation**    |     |                                           |                   |            |
| <7                                    | 12  | 5.22                                      | 1.54              |            |
| ≥7                                    | 18  | 5.75                                      | 1.83              | 0.44       |
| **Intensive care (upon enrolment or during hospitalisation)** | | | | |
| No                                    | 46  | 5.47                                      | 1.78              |            |
| Yes                                   | 4   | 5.59                                      | 0.92              | 0.71       |
| **White blood cells, cells/μL**       |     |                                           |                   |            |
| <15,000                               | 26  | 5.41                                      | 1.73              |            |
| ≥15,000                               | 24  | 5.66                                      | 1.97              | 0.90       |
| **PCR, mg/dL**                        |     |                                           |                   |            |
| <7                                    | 27  | 5.36                                      | 1.76              | 0.85       |
| ≥7                                    | 23  | 5.69                                      | 1.82              |            |
| **RV viremia**                        |     |                                           |                   |            |
| Negative                              | 44  | 5.15                                      | 1.53              |            |
| Positive                              | 6   | 7.90                                      | 1.07              | <0.001     |
| **Type of RV**                        |     |                                           |                   |            |
| A                                     | 18  | 6.46                                      | 1.73              |            |
| B                                     | 5   | 6.83                                      | 1.09              |            |
| C                                     | 22  | 5.96                                      | 1.76              |            |
| Not specified                         | 5   | 4.48                                      | 1.32              | 0.01       |
| Overall                               | 50  | 5.48                                      | 1.72              |            |

*SD standard deviation

*a Calculated using Wilcoxon’s non-parametric rank-sum test or the Kruskal-Wallis test as appropriate

*b Higher than normal was defined as >60 in children aged <1 year, >50 in children aged 1–3 years, and >40 in children aged >3 years
### Table 2: Characteristics of patients with rhinovirus (RV)-positive nasopharyngeal swabs by the presence or absence of RV viremia

| Characteristics                          | Absence of RV viremia, n (%) | Presence of RV viremia, n (%) | P value<sup>a</sup> |
|------------------------------------------|------------------------------|------------------------------|---------------------|
| **Age**                                  |                              |                              |                     |
| <1 year                                  | 15 (34.1)                    | 2 (33.3)                     | 1.00                |
| ≥1 year                                  | 29 (65.9)                    | 4 (66.7)                     |                     |
| **Gender**                               |                              |                              |                     |
| Male                                     | 29 (65.9)                    | 1 (16.7)                     | 0.03                |
| Female                                   | 15 (34.1)                    | 5 (83.3)                     |                     |
| **Diagnosis**                            |                              |                              |                     |
| Upper respiratory tract infection        | 23 (52.2)                    | 2 (33.3)                     |                     |
| Bronchiolitis/bronchitis                 | 9 (20.5)                     | 0 (0.0)                      |                     |
| Pneumonia/bronchopneumonia              | 12 (27.3)                    | 4 (66.7)                     | 0.45                |
| **Respiratory rate upon enrolment<sup>b</sup>** |                              |                              |                     |
| Normal                                   | 16 (80.0)                    | 0 (0.0)                      |                     |
| Higher than normal                      | 4 (20.0)                     | 3 (100.0)                    | 0.02                |
| **O₂ saturation upon enrolment**         |                              |                              |                     |
| <93 %                                    | 4 (9.5)                      | 4 (66.7)                     | 0.005               |
| ≥93 %                                    | 38 (90.5)                    | 2 (33.3)                     |                     |
| **O₂ therapy**                           |                              |                              |                     |
| No                                       | 33 (75.0)                    | 1 (16.7)                     | 0.009               |
| Yes                                      | 11 (25.0)                    | 5 (83.3)                     |                     |
| **No. of days of O₂ therapy**            |                              |                              |                     |
| <3                                       | 2 (16.7)                     | 1 (25.0)                     | 1.00                |
| ≥3                                       | 10 (83.3)                    | 3 (75.0)                     |                     |
| **Hospitalisation**                      |                              |                              |                     |
| No                                       | 18 (40.9)                    | 2 (33.3)                     | 1.00                |
| Yes                                      | 26 (59.1)                    | 4 (66.7)                     |                     |
| **No. of days of hospitalisation**       |                              |                              |                     |
| <7                                       | 10 (41.7)                    | 2 (50.0)                     | 1.00                |
| ≥7                                       | 14 (58.3)                    | 2 (50.0)                     |                     |
| **Intensive care (upon enrolment or during hospitalisation)** |                              |                              |                     |
| No                                       | 43 (97.7)                    | 3 (50.0)                     | 1.00                |
| Yes                                      | 1 (2.3)                      | 3 (50.0)                     |                     |
| **White blood cells, cells/μL**          |                              |                              |                     |
| <15,000                                  | 26 (59.1)                    | 0 (0.0)                      | 0.008               |
| ≥15,000                                  | 18 (40.9)                    | 6 (100.0)                    |                     |
| **C reactive protein, mg/dL**            |                              |                              |                     |
| <7                                       | 27 (61.4)                    | 0 (0.0)                      | 0.006               |
| ≥7                                       | 17 (38.6)                    | 6 (100.0)                    |                     |
| **Nasopharyngeal RV load**               |                              |                              |                     |
| <median (i.e., 5.5 log₁₀ cp/mL)          | 25 (56.8)                    | 0 (0.0)                      | 0.02                |
| ≥median                                  | 19 (43.2)                    | 6 (100.0)                    |                     |
| **Range**                                | 2.44–8.59                    | 5.94–8.85                    |                     |
| **Type of RV**                           |                              |                              |                     |
| A                                        | 17 (38.6)                    | 1 (16.7)                     |                     |
| B                                        | 4 (9.1)                      | 1 (16.7)                     |                     |
| C                                        | 18 (40.9)                    | 4 (66.6)                     |                     |
| Not specified                            | 5 (11.4)                     | 0 (0.0)                      | 0.09                |
| Overall                                  | 44 (88.0)                    | 6 (12.0)                     |                     |

<sup>a</sup> Calculated using the chi-squared or Fisher’s exact test

<sup>b</sup> Higher than normal was defined as >60 in children aged <1 year, >50 in children aged 1–3 years, and >40 in children aged >3 years.
RV load and the severity of lower RTIs has been previously reported by van Elden et al. in adults with asthma [13]. However, these data and those collected by us are different from the data published by other authors [14, 16]. Gerna et al. found that RVs were mainly associated with lower RTIs (in the absence of other viral agents) and wheezing in immunocompetent pediatric patients with nasopharyngeal loads of ≥6 log_{10} RNA copies/mL, whereas lower values represented a probable carrier state in immunocompromised asymptomatic adult patients [14]. Similarly, Takeyama et al. found a significant positive correlation between nasopharyngeal RV load and disease severity in patients aged ≥11 months, but not in younger patients [16]. Finally, Kieninger et al. studied the bronchoalveolar lavages of patients with severe chronic respiratory disease and healthy controls, and found that patients with cystic fibrosis or bronchiectasis had higher RV loads in respiratory secretions than controls, particularly during pulmonary exacerbations, whereas asthmatic patients had similar loads to those measured in healthy subjects [19]. On the basis of our findings, it is possible that these discrepancies may be at least partially due to the different number of viremic patients enrolled in each study, although none of the previous studies simultaneously evaluated nasopharyngeal RV load and RV viremia.

RVs have been traditionally associated with RTIs, and extra-respiratory localisations have been considered relatively unimportant. However, they have recently been linked to pericarditis [28], and RVs have been found in stool samples of children with gastroenteritis, thus suggesting that they may be the cause of diarrhea [15].

Viremia during respiratory RV infection has been studied over recent years but, when RVs could only be identified by means of culture, it was only found in a very small number of children who died suddenly and unexpectedly [29, 30], or because of an acute RTI [31]. Current molecular methods are significantly more sensitive and, contrary to expectations, have revealed that viremia is relatively common in children with RV infection and is usually associated with a more severe course of RV disease. Xatzipsalti et al. detected RV in the blood of 11.4 % of 88 children with upper and lower RTIs, particularly during the early course of disease, and found that it was mainly associated with a significant increase in moderate or severe exacerbations of acute asthma [17]. Similarly, Fuji et al. found that 12.3 % of 243 subjects with RV infection and severe respiratory symptoms were viremic, most of whom had reduced O_{2} blood saturation levels [20]. They also found that RV-C was more frequently associated with viremia than RV-A and RV-B, thus suggesting that it may be more pathogenic.

Our findings confirm that viremia is relatively common in RV-positive patients and that it seems to be a marker of more severe RV disease, particularly when the infection is caused by RV-C. The prevalence of viremia in our study was 12 %, which is practically identical to previously reported prevalence, and most of the viremic patients had RV-C infection [20]. Interestingly, the children who were viremic upon admission not only had a worse clinical presentation and a higher

| Type of rhinovirus | Absence of RV viremia | Presence of RV viremia | P value\(^a\) |
|-------------------|-----------------------|------------------------|----------|
| RV-A load (n=18)  | 9 (52.9) <median (i.e., 6.16 log_{10} cp/mL), n (%) | 0 (0.0) ≥median, n (%) | 1.00     |
|                   | 3.90–8.59 Range       | 8.83                   | 12.15    |
|                   | Mean (SD) 5.83 (1.57)  | 8.83 (–)               | 0.15     |
| RV-B load (n=5)   | 3 (75.0) <median (i.e., 7.26 log_{10} cp/mL), n (%) | 0 (0.0) ≥median, n (%) | 0.33     |
|                   | 5.59–7.26 Range       | 7.64                   | 0.54     |
|                   | Mean (SD) 6.42 (1.18)  | 7.64 (–)               | 0.03     |
| RV-C load (n=22)  | 12 (66.7) <median (i.e., 5.91 log_{10} cp/mL), n (%) | 0 (0.0) ≥median, n (%) | 0.08     |
|                   | 2.44–8.38 Range       | 5.94–8.85              | 0.03     |
|                   | Mean (SD) 5.38 (1.51)  | 7.73 (1.25)            | 0.03     |
| RV-unspecified load (n=5) | 2 (40.0) <median (i.e., 4.48 log_{10} cp/mL), n (%) | 0 (0.0) ≥median, n (%) | –        |
|                   | 2.44–7.50 Range       | 4 (100.0)              | –        |
|                   | Mean (SD) 4.48 (1.32)  | 4 (100.0)              | –        |

SD standard deviation
\(^a\)Calculated using Fisher’s exact test.
incidence of low O₂ saturation levels, but also had significantly higher WBC counts, CRP levels and nasopharyngeal RV loads. Blood culture for bacteria was negative in all the cases. This finding, although it does not exclude the possible coexistence of a bacterial co-infection due to the poor sensitivity of culture in the identification of bacteremic cases [32], supports the hypothesis that RV was the cause of the disease. On the other hand, in viremic cases RV was the only virus identified both in the nasopharyngeal swab and in the blood.

In conclusion, the findings of this study suggest that nasopharyngeal viral load and viremia influence the severity of RV infection. However, further studies are needed to verify the relationships between viremia and duration of signs and symptoms of disease, duration of viral shedding and risk of superimposed bacterial infections. This information could be useful to decide characteristics of RV-related disease and its outcome.

Acknowledgments This study was supported by a grant from the Italian Ministry of Health (Bando Giovanni Ricercatori 2009).

Conflict of interest The authors declare that they have no conflict of interest.

References

1. Kennedy JL, Turner RB, Braciale T, Heymann PW, Borish L (2011) Pathogenesis of rhinovirus infection. Curr Opin Virol 2:287–293
2. Mahony JB, Petrich A, Smieja M (2011) Molecular diagnosis of respiratory virus infections. Crit Rev Clin Lab Sci 48:217–49
3. Turner RB, Lande AE, Chase P, Hilton N, Weinberg D (1987) Pneumonia in pediatric outpatients: cause and clinical manifestations. J Pediatr 111:194–200
4. Cheuk DK, Rang IW, Chan KH, Woo PC, Peiris MJ, Chiu SS (2007) Rhinovirus infection in hospitalized children in Hong Kong: a prospective study. Pediatr Infect Dis J 26:995–1000
5. Hayden FG (2004) Rhinovirus and the lower respiratory tract. Rev Med Virol 14:17–31
6. Esposito S, Daleno C, Tagliabue C, Scala A, Tenconi R, Borzani I, Fossali E, Pelucchi C, Piralla A, Principi N (2012) Impact of rhinoviruses on pediatric community-acquired pneumonia. Eur J Clin Microbiol Infect Dis 31:1637–45
7. Brownlee JW, Turner RB (2008) New developments in the epidemiology and clinical spectrum of rhinovirus infections. Curr Opin Pediatr 20:67–71
8. Esposito S, Daleno C, Prunotto G, Scala A, Tagliabue C, Borzani I, Fossali E, Pelucchi C, Principi N (2013) Impact of viral infections in children with community-acquired pneumonia: results of a study of 17 respiratory viruses. Influenza Other Respir Viruses 7:18–26
9. Johnston SL, Sanderson G, Pattmore PK, Smith S, Bardin PG, Bruce CB, Lambden PR, Tyrell DA, Holgate ST (1993) Use of polymerase chain reaction for diagnosis of picornavirus infection in subjects with and without respiratory symptoms. J Clin Microbiol 31:111–117
10. Nokso-Koivisto J, Kinnari TJ, Lindahl P, Hovi T, Pitkäranta A (2002) Human picornavirus and coronavirus RNA in nasopharynx of children without concurrent respiratory symptoms. J Med Virol 66:417–420
11. van Benten I, Koopman L, Niesters B, Hop W, van Middelkoop B, de Waal L, van Drunen K, Osterhaus A, Neijens H, Fokkens W (2003) Predominance of rhinovirus in the nose of symptomatic and asymptomatic infants. Pediatr Allergy Immunol 14:363–370
12. Wright PF, Deatly AM, Karron RA, Belshe RB, Shi JR, Gruber WC, Zhu Y, Randolph VB (2007) Comparison of results of detection of rhinovirus by PCR and viral culture in human nasal wash specimens from subjects with and without clinical symptoms of respiratory illness. J Clin Microbiol 45:2126–2129
13. van Elden LJ, Sachs AP, van Loon AM, Haarman M, van de Vijver DA, Kimman TG, Zuithoff P, Schipper PJ, Verheij TJJ, Nijhuis M (2008) Enhanced severity of virus associated lower respiratory tract disease in asthma patients may not be associated with delayed viral clearance and increased viral load in the upper respiratory tract. J Clin Virol 41:116–121
14. Gerna G, Piralla A, Rovida F, Rognoni V, Marchi A, Locatelli F, Meloni F (2009) Correlation of rhinovirus load in the respiratory tract and clinical symptoms in hospitalized immunocompetent and immunocompromised patients. J Med Virol 81:1498–1507
15. Harvala H, McIntyre CL, McLeish NJ, Kondracka J, Palmer J, Molyneaux P, Gunson R, Bennett S, Templeton K, Simmonds P (2012) High detection frequency and viral loads of human rhinovirus species A to C in faecal samples; diagnostic and clinical implications. J Med Virol 84:536–542
16. Takeyama A, Hashimoto K, Sato M, Sato T, Kanno S, Takano K, Ito M, Katayose M, Nishimura H, Kakawaki Y, Hosoya M (2012) Rhinovirus load and disease severity in children with lower respiratory tract infections. J Med Virol 84:1135–1142
17. Xatzipsalti M, Kyranis S, Tsolias M, Psarras S, Bossios A, Laza-Stanca V, Johnston SL, Papadopoulos NG (2005) Rhinovirus viremia in children with respiratory infections. Am J Respir Crit Care Med 172:1037–1040
18. Message SD, Laza-Stanca V, Mallia P, Parker HL, Zhu J, Kebadze T, Contoli M, Sanderson G, Kon OM, Papi A, Jeffery PK, Stanciu LA, Johnston SL (2008) Rhinovirus-induced lower respiratory illness is increased in asthma and related to virus load and TH1/2 cytokine and IL-10 production. Proc Natl Acad Sci USA 105:13562–13567
19. Kieninger E, Singer F, Tapparel C, Alves MP, Latzin P, Tan HL, Bossley C, Casaula C, Bush A, Davies JC, Kaiser L, Regamey N (2013) High rhinovirus burden in lower airways of children with cystic fibrosis. Chest 143:782–90
20. Fuji N, Suzuki A, Lupisan S, Sombrero L, Galang H, Kamigaki T, Saito M, Aniceto R, Olveda R, Oshitani H (2011) Detection of human rhinovirus C viral genome in blood among children with severe respiratory infections in the Philippines. PLoS One 6:e27247
21. Feigin RD, Cherry JD (eds) (2009) Textbook of pediatric infectious diseases, 6th ed. W. B. Saunders Company, Philadelphia
22. World Health Organization (2001) Pneumonia vaccine trial investigators’ group. Standardization of interpretation of chest radiographs for the diagnosis of pneumonia in children. WHO/V&B/01.35. World Health Organization, Geneva
23. Munywoki PK, Hamid F, Mutunga M, Welch S, Cane P, Nokes DJ (2011) Improved detection of respiratory viruses in pediatric outpatients with acute respiratory illness by real-time PCR using nasopharyngeal flocked swabs. J Clin Microbiol 49:3365–7
24. Esposito S, Cohen R, Domingo JD, Pecurarui OF, Greenberg D, Heininger U, Knuf M, Lutsar I, Principi N, Rodrigues F, Sharland M, Spoulou V, Syrogiannopoulos GA, Usonis V, Vergison A, Schaad UB (2012) Antibiotic therapy for pediatric community-acquired pneumonia: do we know when, what and for how long to treat? Pediatr Infect Dis J 31:e78–85
25. Gadsby NJ, Hardie A, Claas EC, Templeton KE (2010) Comparison of the Luminex respiratory virus panel fast assay with in-house real-time PCR for respiratory viral infection diagnosis. J Clin Microbiol 48:2213–6
26. Pabbaraju K, Wong S, Tokaryk KL, Fonseca K, Drews SJ (2011) Comparison of the Luminex xTAG respiratory viral panel with xTAG respiratory viral panel fast for diagnosis of respiratory virus infections. J Clin Microbiol 49:1738–44
27. Lu X, Holloway B, Dare RK, Kuypers J, Yagi S, Williams JV, Hall CB, Erdman DD (2008) Real-time reverse transcription-PCR assay for comprehensive detection of human rhinoviruses. J Clin Microbiol 46:533–9
28. Savolainen C, Blomqvist S, Mulders MN, Hovi T (2002) Genetic clustering of all 102 human rhinovirus prototype strains: serotype 87 is close to human enterovirus 70. J Gen Virol 83(Pt 2):333–40
29. Tapparel C, L’Huillier AG, Rougemont AL, Beghetti M, Barazzone-Argiroffo C, Kaiser L (2009) Pneumonia and pericarditis in a child with HRV-C infection: a case report. J Clin Virol 45:157–60
30. Urquhart G, Stott E (1970) Rhinoviraemia. BMJ 4:28–30
31. Urquhart G, Grist N (1972) Virological studies of sudden, unexplained infant deaths in Glasgow 1967–70. J Clin Pathol 25:443–446
32. Esposito S, Marchese A, Tozzi AE, Rossi GA, Da Dalt L, Bona G, Pelucchi C, Schito GC, Principi N (2012) Bacteremic pneumococcal community-acquired pneumonia in children less than 5 years of age in Italy. Pediatr Infect Dis J 31:705–710